NASHVILLE, Tenn., Jan. 26 /PRNewswire/ -- Cumberland Emerging
Technologies, Inc. (CET) is pleased to announce that Microbial Novoteqs,
Inc. is expanding its presence as a tenant at the downtown CET Life
Sciences Center. The company will lease additional wet lab and office space
in the newly expanded facility, which is adjacent to the Union Station
Launched in late 2006 by former Vanderbilt professor of microbiology
Hong Fang Ph.D., Microbial Novoteqs works to develop and utilize more
economic and efficient technologies for the discovery of drugs to fight
global infectious diseases. The company, which is being awarded a
three-year grant from the National Institutes of Health (NIH) estimated at
over $1 million, plans to add two senior scientists devoted to research
efforts supported by the grant.
The NIH grant will fund study of the development of protease inhibitors
to block the enzymes that infectious diseases need to replicate and infect
new cells. Similar research has resulted in the development of protease
inhibitor drugs that, taken in combination with other drugs, have helped
reduce the number of HIV patients who became ill from opportunistic
infections by nearly 70 percent. Other infectious diseases which the
company's research will target include Dengue fever, Hepatitis A, Japanese
encephalitis, Norwalk virus, SARS, West Nile virus and Yellow fever.
"This is a very exciting time for our company," said Dr. Fang, who
serves as president and chief executive officer of Microbial Novoteqs. "Our
research strategy has the potential to dramatically decrease time and
reduce costs between drug discovery and patient use. CET's ability to
provide infrastructure support and resources necessary at this stage, as
well as their experience with the commercialization process, makes them an
ideal partner for our company."
The CET Life Sciences Center now provides lab and office space,
equipment and infrastructure support to seven tenants, including the
Tennessee Biotechnology Association, which has established its headquarters
at the center.
"We are delighted that Microbial Novoteqs has the need for additional
space at our Life Sciences Center, and will be bringing new jobs to the
facility," said A.J. Kazimi, CEO of CET and Cumberland Pharmaceuticals.
"They are an excellent example of the type of tenant our facility was
created to assist. As they grow and gain momentum, we're pleased we can
play an integral role in furthering their potentially life-saving
Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint
initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc.
and the Tennessee Technology Development Corporation. The mission of CET is
to bring biomedical technologies and products conceived at Vanderbilt and
other regional research centers to the marketplace. CET helps manage the
development and commercialization process for select projects, and provides
expertise on intellectual property, regulatory, manufacturing and marketing
issues that are critical to successful new biomedical products. CET's Life
located in Nashville, Tennessee, provides laboratory space, equipment
and infrastructure to early-stage life sciences companies.
SOURCE Cumberland Emerging Technologies, Inc.